The Society for Immunotherapy of Cancer (SITC) hosted the Approaches to Early-stage Malignancies, Driving to a Cure Industry Program during the 38th Annual Meeting & Pre-Conference Programs on November 1, 2023. Available here are the presentation slides and video from “Session 1: Review of Early-stage Disease, What We've Learned, Recent Approvals in the Perioperative Setting” as permitted by presenters.
Nicholas Botwood, MD – Bristol Myers Squibb
Jane Anne Healy, MD, PhD – Merck Sharp & Dhome LLC
Giovanni Melillo, MD – AstraZeneca
The target audience for this program includes researchers from academia and industry involved in basic, translational and clinical research, as well as clinicians and those from regulatory and funding agencies.
The SITC 2023 Industry Program, “Approaches to Early-stage Malignancies, Driving to a Cure,” will advance the science and application of cancer immunotherapy by bringing together high-level experts to provide high-level perspective surrounding cancer immunotherapy for early-stage disease. The program will explore recent translational and clinical studies of immunotherapy in the perioperative setting and the knowledge gained from these studies, including the identification and validation of predictive biomarkers and the development of surrogate endpoints for clinical trials. The program will also address statistical and regulatory considerations when designing clinical trials of cancer immunotherapy in the perioperative setting. Armed with a deeper understanding of cancer immunotherapy as treatment for early-stage malignancies, attendees will be equipped to develop cancer immunotherapy-based treatment strategies that are cost-efficient, faster, safer, and more effective for patients.
At the conclusion of this activity, participants should be able to:
To view the entire program schedule (including presenter permission to post) please click here.
Meeting: World Immunotherapy Council (WIC) Young Investigator Symposium; Session: 1; Date: November 1, 202301:06:22